A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2004
12/23/2004	US20040258694 Hepatitis C receptor protein CD81
12/23/2004	US20040258691 Treating psoriasis in a patient by administering a therapeutically effective amount of an antibody immunospecific for vetronectin receptor av beta 3; antiinflammatory agents; antibody does not immunoreact with integrins other than av beta 3; cell adhesion
12/23/2004	US20040258690 Coagulants comprising a synergistic combination for treatment or prophylaxis of bleeding episodes and coagulation disorders, e.g., liver disorders; von Wildebrand disease, surgery, trauma,blood disorders; hemostatic agents; side effect reduction; single-unit dosage; kits; Fab fragments and antibodies
12/23/2004	US20040258688 Long lasting immunity using single dose at low concentration; exposing dendritic cells to antigen-antibody-DEC-205 receptor conjugate or to recombinant anti-DEC-205 antibody and promoting maturation
12/23/2004	US20040258687 Use of GCC ligands
12/23/2004	US20040258686 Mammalian receptor proteins; related reagents and methods
12/23/2004	US20040258684 Agonist antibodies
12/23/2004	US20040258683 Administering epitope that maintains sustained reduction of circulating anti-dsDNA antibodies; reducing risk of renal flare
12/23/2004	US20040258682 Monoclonal antibody or fragment engineered in non-Fc constant heavy or light region; immunoconjugates for cancer diagnosis and therapy
12/23/2004	US20040258681 Nucleic acid and amino acid sequences; purified antibodies, expression vectors, host cells
12/23/2004	US20040258680 Methos of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogoues, isoforms and other derivatives
12/23/2004	US20040258679 Nucleic and amino acid sequences; autoimmune/inflammatory disorders, cancer; expression vectors, host cells, antibodies, agonists, antagonists. transgenic organisms
12/23/2004	US20040258678 Isolated nucleic acid having high identity to sequence 215; vectors, host cells, antibodies
12/23/2004	US20040258676 Stimulation of the activity of an isoform of lysyl oxidase for combating against some pathologies due to an incomplete, absent or disorganized elastogenesis
12/23/2004	US20040258675 Novel mutated form of arginine deiminase
12/23/2004	US20040258672 Graft acceptance through manipulation of thymic regeneration
12/23/2004	US20040258671 Delivering antiinflammatory cytokines to nervous system using gene therapy techniques
12/23/2004	US20040258670 Introducing enriched human endothelial generating cells and mesenchymal stem cells; enhancing vasculogenesis and collateralization around blocked and/or narrowed vessels
12/23/2004	US20040258667 Herpes simplex virus expressing foreign genes and method for treating cancers therewith
12/23/2004	US20040258666 Injecting adeno-associated virus vectors into central nervous system; transducing cells located at distal site for translation of biologically active molecule and expression; Niemann-Pick A disease
12/23/2004	US20040258665 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
12/23/2004	US20040258663 Maintaining sustained levels and optimizing intranasal dosing schedules without causing intolerable side effects
12/23/2004	US20040258662 Antineoplastic agents
12/23/2004	US20040258659 Design and/or selection of phage agonists or antagonists towards G protein coupled receptor ligands; enhanced anti-HIV-1 activity compared to RANTES
12/23/2004	US20040258656 Identified via SELEX method; phosphate-containing ligand is conjugated to polyoxyethylene glycol; transforming growth factor (TGF); pharmacokinetics
12/23/2004	US20040258623 Microemulsion containing soybean lecithin as absorption promoter, propylene glycol cosolvent and phosphate buffer; bioavailability, stability, low toxicity; produced by sonication
12/23/2004	US20040258621 Method of treating snoring and other obstructive breathing disorders
12/23/2004	US20040258619 Diaminedioxime radiometal complexes
12/23/2004	DE10325049A1 New peptide derivatives containing cell-adhesion molecule and phosphonate-containing anchor component, useful for treating disorders associated with implants, are inhibitors of integrins
12/23/2004	DE10324997A1 Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden MRP8 / MRP14 inhibitors and their use for the prevention and / or treatment of hypertrophic scars and keloids
12/23/2004	DE10324861A1 Composition for treating breast tumors, comprises a peptide toxin from the spider Lycosa tarantula, also an antagonist of the peptide and/or penetration agent
12/23/2004	DE10324256A1 Lipid-Tranferprotein-Systeme und deren kosmetische/dermatologische Anwendung Lipid Tranferprotein systems and their cosmetic / dermatological use
12/23/2004	DE10235248B4 Fusionsprotein mit verstärkter in vivo-Aktivität von Erythropoietin Fusion protein with enhanced in vivo activity of erythropoietin
12/23/2004	CA2563361A1 Cell permeable conjugates of peptides for inhibition of protein kinases
12/23/2004	CA2536357A1 Targeted delivery to legumain-expressing cells
12/23/2004	CA2531890A1 Peptides enhancing ceh activity or inhibiting acat activity for treating atherosclerosis
12/23/2004	CA2530972A1 Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
12/23/2004	CA2529972A1 Polymeric conjugates for tissue activated drug delivery
12/23/2004	CA2529828A1 Factor vii or viia gla domain variants
12/23/2004	CA2529814A1 Chemokine-binding protein thap1, methods and use thereof
12/23/2004	CA2529496A1 Anti-cd74 immunoconjugates and methods
12/23/2004	CA2529478A1 Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
12/23/2004	CA2529125A1 Antimicrobial and anticancer lipopeptides
12/23/2004	CA2528883A1 Pharmaceutical compositions for preventing or treating th1-mediated immune diseases
12/23/2004	CA2528844A1 Novel phosphorylated sequences of the phosphatase cdc25b, antibodies for said sequences and use thereof
12/23/2004	CA2528427A1 Modified human acid sphingomyelinase having increased activity, and methods for making the same
12/23/2004	CA2528402A1 Sphingoid polyalkylamine conjugates for vaccination
12/23/2004	CA2528375A1 Macrocyclic antagonists of the motilin receptor
12/23/2004	CA2528235A1 Connective tissue derived polypeptides
12/23/2004	CA2528186A1 Molecules for targeting and releasing therapeutic compounds, and the use thereof
12/23/2004	CA2527869A1 Method for the treatment of malignancies
12/23/2004	CA2527847A1 Enhancement of oligodendrocyte differentiation
12/23/2004	CA2527843A1 Immunotherapeutics for biodefense
12/23/2004	CA2527830A1 Therapeutic vaccine compositions for the treatment of type 1 diabetes
12/23/2004	CA2526169A1 Fusion proteins
12/23/2004	CA2525966A1 Novel immunomodulating peptide
12/23/2004	CA2525784A1 Proteoglycan degrading mutants for treatment of cns
12/23/2004	CA2525782A1 Degradation of glycosaminoglycans in extracellular matrix to treat cns injury
12/23/2004	CA2525517A1 Use of prion conversion modulating agents
12/23/2004	CA2525017A1 Needleless syringe having medical agent accommodated therein
12/23/2004	CA2520148A1 Compositions and methods for treating coronavirus infection and sars
12/23/2004	CA2519875A1 Method of tumor regression with vegf inhibitors
12/23/2004	CA2514288A1 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
12/22/2004	EP1489189A1 Diagnostics and remedies for malignant brain tumor
12/22/2004	EP1489185A1 Methods and compositions for use in splicesome mediated rna trans-splicing
12/22/2004	EP1489183A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
12/22/2004	EP1489180A1 P18abeta rp gene and p18abeta rp protein, novel gene/protein (p60trp) interacting therewith to inhibit cell death and cell death promoter
12/22/2004	EP1489179A1 Antiopoietin-related growth factor
12/22/2004	EP1489172A1 Nuclear receptor err gamma 3
12/22/2004	EP1489170A1 Transporter selectively transporting sulfate conjugate and its gene
12/22/2004	EP1489100A2 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
12/22/2004	EP1489099A2 Antibodies that bind the CD40CR receptor
12/22/2004	EP1489097A1 Inhibitors of human plasmin derived from kunitz domains and nucleic acids encoding the same
12/22/2004	EP1489096A1 Novel hemepeptide
12/22/2004	EP1489093A1 Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer
12/22/2004	EP1488807A1 Remedies for sex hormone-dependent disease
12/22/2004	EP1488805A2 CD28 pathway immunoregulation
12/22/2004	EP1488803A1 Neurotoxic component of botulinum toxins for treating neuromuscular disorders
12/22/2004	EP1488801A1 Chemical igf-i composition for the treatment and prevention of neurodegenerative diseases
12/22/2004	EP1488800A1 Agent for the treatment of protozoal diseases
12/22/2004	EP1488799A2 Soluble lymphotosin-Beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
12/22/2004	EP1488798A1 HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
12/22/2004	EP1488761A1 Device for delivering a therapeutic agent to a blood vessel
12/22/2004	EP1488239A2 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
12/22/2004	EP1487992A2 Central airway administration for systemic delivery of therapeutics
12/22/2004	EP1487991A2 Cancer-linked gene as target for chemotherapy
12/22/2004	EP1487986A2 METHOD OF PREPARING A TREATMENT PRODUCT, TREATMENT PRODUCT AND A PLASMID CONSTRUCT
12/22/2004	EP1487984A1 Dna vaccines encoding cea and a cd40 ligand and methods of use thereof
12/22/2004	EP1487983A2 Prevention of recurrence and metastasis of cancer
12/22/2004	EP1487981A2 Growth regulating proteins
12/22/2004	EP1487979A1 Constructs and methods for the regulation of gene expression
12/22/2004	EP1487971A2 MEANS AND METHODS FOR MANIPULATING HYPERSENSITIVITY−LIKE RESPONSES
12/22/2004	EP1487964A2 POLYNUCLEOTIDE ENCODING A NOVEL HUMAN POTASSIUM CHANNEL ALPHA-SUBUNIT, K+alphaM1, AND VARIANTS THEREOF
12/22/2004	EP1487874A1 Falp proteins
12/22/2004	EP1487872A1 Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
12/22/2004	EP1487870A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
12/22/2004	EP1487867A2 Modified plasminogen activator inhibitor type-1 and methods based thereon
12/22/2004	EP1487865A2 USES OF MAMMALIAN CYTOKINEi; RELATED REAGENTS
12/22/2004	EP1487864A2 Therapeutic polypeptides nucleic acids encoding same, and methods of use
12/22/2004	EP1487863A2 Process for purifying glycopeptide phospohonate derivatives

1 ... 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 ... 3163